PT - JOURNAL ARTICLE AU - Vincent Legros AU - Solène Denolly AU - Manon Vogrig AU - Bertrand Boson AU - Josselin Rigaill AU - Sylvie Pillet AU - Florence Grattard AU - Sylvie Gonzalo AU - Paul Verhoeven AU - Omran Allatif AU - Philippe Berthelot AU - Carole Pélissier AU - Guillaume Thierry AU - Elisabeth Botelho-Nevers AU - Stéphane Paul AU - Thierry Walzer AU - François-Loïc Cosset AU - Thomas Bourlet AU - Bruno Pozzetto TI - A longitudinal study of SARS-CoV-2 infected patients shows high correlation between neutralizing antibodies and COVID-19 severity AID - 10.1101/2020.08.27.20182493 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.27.20182493 4099 - http://medrxiv.org/content/early/2020/09/01/2020.08.27.20182493.short 4100 - http://medrxiv.org/content/early/2020/09/01/2020.08.27.20182493.full AB - Understanding the immune responses elicited by SARS-CoV-2 infection is critical in terms of protection from re-infection and, thus, for public health policy and for vaccine development against the COVID-19. Here, using either live SARS-CoV-2 particles or retroviruses pseudotyped with the SARS-CoV-2 S viral surface protein (Spike), we studied the neutralizing antibody (nAb) response in serum specimens from a cohort of 140 SARS-CoV-2 qPCR-confirmed patients, including patient with mild symptoms but also more severe form including those that require intensive care. We show that nAb titers were strongly correlated with disease severity and with anti-Spike IgG levels. Indeed, patients from intensive care units exhibited high nAb titers, whereas patients with milder disease symptoms displayed heterogenous nAb titers and asymptomatic or exclusive outpatient care patients had no or poor nAb levels. We found that the nAb activity in SARS-CoV-2-infected patients displayed a relatively rapid decline after recovery, as compared to individuals infected with alternative coronaviruses. We show the absence of cross-neutralization between endemic coronaviruses and SARS-CoV-2, indicating that previous infection by human coronaviruses may not generate protective nAb against SARS-CoV-2 infection. Finally, we found that the D614G mutation in the Spike protein, which has recently been identified as the major variant now found in Europe, does not allow neutralization escape. Altogether, our results contribute to the understanding of the immune correlate of SARS-CoV-2 induced disease and claim for a rapid evaluation of the role of the humoral response in the pathogenesis of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe laboratory of FLC received financial support from the LabEx Ecofect (ANR-11-LABX-0048) of the “Université de Lyon”, within the program “Investissements d’Avenir” (ANR-11-IDEX-0007) operated by the French National Research Agency (ANR), the ANR (grant from RA-Covid-19), the Fondation pour la Recherche Médicale (FRM), and Inserm TransfertAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethical Committee of the University Hospital of Saint-Etienne (reference number IRBN512020/CHUSTE).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request